Creative Planning Buys 19,194 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Creative Planning increased its stake in Arrowhead Pharmaceuticals by 72.5% in Q2, owning 45,662 shares valued at $721,000. Other hedge funds also adjusted their positions. Insiders sold 43,750 shares worth $1.64 million. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $53.33. Arrowhead's stock opened at $57.95, with a market cap of $7.87 billion.

Creative Planning grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 72.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,662 shares of the biotechnology company's stock after purchasing an additional 19,194 shares during the period. Creative Planning's holdings in Arrowhead Pharmaceuticals were worth $721,000 at the end of the most recent reporting period.

Want Diversified Upside in Biotechnology? Check out LABU

A number of other hedge funds also recently made changes to their positions in ARWR. Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,308 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after purchasing an additional 1,214 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Arrowhead Pharmaceuticals in the first quarter valued at $133,000. Pale Fire Capital SE bought a new stake in Arrowhead Pharmaceuticals in the first quarter worth $156,000. Finally, Bryce Point Capital LLC purchased a new stake in Arrowhead Pharmaceuticals during the second quarter valued at $164,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Mauro Ferrari sold 8,750 shares of the firm's stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $56.39, for a total value of $493,412.50. Following the transaction, the director owned 68,764 shares of the company's stock, valued at $3,877,601.96. This trade represents a 11.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider owned 212,122 shares of the company's stock, valued at $7,424,270. The trade was a 8.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 43,750 shares of company stock valued at $1,643,413. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on ARWR shares. HC Wainwright lifted their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a "buy" rating in a research note on Tuesday. Piper Sandler lifted their price target on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada raised their price objective on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an "outperform" rating in a research note on Wednesday, November 19th. Finally, The Goldman Sachs Group lifted their target price on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a "neutral" rating in a report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.33.

View Our Latest Report on ARWR

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $57.95 on Wednesday. The stock has a 50 day moving average price of $40.14 and a 200 day moving average price of $26.63. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $59.27. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The firm has a market capitalization of $7.87 billion, a P/E ratio of -724.28 and a beta of 1.28.

About Arrowhead Pharmaceuticals

(Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Five stocks we like better than Arrowhead Pharmaceuticals
How is Compound Interest Calculated?
Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?
Do ETFs Pay Dividends? What You Need to Know
Checkmate in the Cloud: ServiceNow's Shopping Spree
How the NYSE and NASDAQ are Different, Why That Matters to Investors
The Contrarian Case for MSTR Amid MSCI Delisting Debacle

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here